Insider trading

Period: 120 months Stock: WVE Plan: Not on a plan × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

78 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

78 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

78 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

78 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
78 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
78 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

78 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$6.31M 971,091 at 6.50
3.7%
27 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$16.05M 2,495,623 at 6.43
10.6%
26 Mar 2026
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought 2×
$32.27M 5,305,782 at 6.08
29.1%
Largest buy in 3 yrs
9 Feb 2026
BOLNO PAUL President and CEO
Sold at will
$140.96K 10,480 at 13.45
3.7%
Not planned
9 Feb 2026
Moran Kyle Chief Financial Officer
Sold at will
$48.26K 3,588 at 13.45
2.6%
Not planned
9 Feb 2026
Vargeese Chandra See Remarks
Sold at will
$43.42K 3,228 at 13.45
0.8%
Not planned
9 Feb 2026
Francis Chris See Remarks
Sold at will
$25.33K 1,883 at 13.45
3.0%
Not planned
11 Dec 2025
GSK plc 10% owner · indirect
Bought
$27.93M 1,470,000 at 19.00
8.8%
Largest buy in 3 yrs
13 Nov 2025
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$6.69K 1,000 at 6.69
0.0%
27 Sep 2024
GSK plc 10% owner · indirect
Bought
$22.34M 2,791,930 at 8.00
20.0%
Largest buy in 3 yrs
11 Dec 2023
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$5.00M 1,000,000 at 5.00
5.5%
7 Dec 2023
GSK plc 10% owner · indirect
Bought
$16.50M 3,300,000 at 5.00
30.9%
First buy on file
16 Feb 2023
BOLNO PAUL President and CEO
Sold, plan not stated
$118.78K 29,400 at 4.04
6.7%
16 Feb 2023
Francis Chris See Remarks
Sold, plan not stated
$41.34K 10,258 at 4.03
11.4%
16 Feb 2023
Vargeese Chandra See Remarks
Sold, plan not stated
$41.30K 10,249 at 4.03
8.8%
16 Feb 2023
Moran Kyle Chief Financial Officer
Sold, plan not stated
$39.31K 9,729 at 4.04
10.9%
16 Jun 2022
RA CAPITAL MANAGEMENT, L.P. Director · indirect
Bought
$20.38M 9,480,052 at 2.15
123%
First buy on file
5 May 2022
BOLNO PAUL President and CEO
Sold, plan not stated
$57.62K 33,501 at 1.72
7.1%
5 May 2022
Panzara Michael A. See Remarks
Sold, plan not stated
$28.75K 16,714 at 1.72
13.3%
5 May 2022
Vargeese Chandra See Remarks
Sold, plan not stated
$28.75K 16,714 at 1.72
13.1%
5 May 2022
Francis Chris See Remarks
Sold, plan not stated
$18.69K 10,867 at 1.72
10.8%
5 May 2022
Moran Kyle Chief Financial Officer
Sold, plan not stated
$8.64K 5,021 at 1.72
5.6%
16 Feb 2022
BOLNO PAUL President and CEO
Sold, plan not stated
$76.91K 33,150 at 2.32
8.1%
16 Feb 2022
Vargeese Chandra Chief Technology Officer
Sold, plan not stated
$24.60K 10,603 at 2.32
12.0%
16 Feb 2022
Panzara Michael A. See Remarks
Sold, plan not stated
$24.49K 10,603 at 2.31
12.3%
16 Feb 2022
Francis Chris See Remarks
Sold, plan not stated
$23.38K 10,123 at 2.31
12.9%
16 Feb 2022
Moran Kyle Chief Financial Officer
Sold, plan not stated
$21.26K 9,204 at 2.31
11.0%
16 Feb 2021
BOLNO PAUL President and CEO
Sold, plan not stated
$118.44K 11,205 at 10.57
2.7%
16 Feb 2021
Vargeese Chandra Chief Technology Officer
Sold, plan not stated
$33.24K 3,145 at 10.57
3.6%
16 Feb 2021
Panzara Michael A. See Remarks
Sold, plan not stated
$30.96K 2,929 at 10.57
3.3%
16 Feb 2021
Francis Chris See Remarks
Sold, plan not stated
$28.52K 2,698 at 10.57
3.3%
16 Feb 2021
Moran Kyle Chief Financial Officer
Sold, plan not stated
$18.20K 1,722 at 10.57
2.4%
15 Sep 2020
BOLNO PAUL President and CEO
Sold, plan not stated
$1.50M 100,000 at 15.00
26.9%
25 Aug 2020
BOLNO PAUL President and CEO
Sold, plan not stated
$300.00K 25,000 at 12.00
8.4%
2 Jul 2020
BOLNO PAUL President and CEO
Sold, plan not stated 4×
$1.52M 147,577 at 10.30
35.2%
18 Feb 2020
BOLNO PAUL President and CEO
Sold, plan not stated
$89.89K 11,451 at 7.85
3.5%
18 Feb 2020
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$25.03K 3,188 at 7.85
7.9%
18 Feb 2020
Panzara Michael A. Chief Medical Officer
Sold, plan not stated
$23.40K 2,981 at 7.85
7.0%
18 Feb 2020
Francis Chris See Remarks
Sold, plan not stated
$21.26K 2,708 at 7.85
8.0%
3 Feb 2020
Gaiero David G Interim CFO
Sold, plan not stated
$4.56K 651 at 7.00
9.2%
3 Dec 2019
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$210.00K 6,000 at 35.00
13.0%
20 Nov 2019
Sold, plan not stated 3×
$920.21K 30,039 at 30.63
50.0%
Sold half or more
5 Jul 2019
Panzara Michael A. Chief Medical Officer
Sold, plan not stated 2×
$82.37K 3,058 at 26.94
6.7%
15 Mar 2019
BOLNO PAUL President and CEO
Sold, plan not stated 4×
$2.27M 50,000 at 45.48
13.1%
11 Mar 2019
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$336.00K 7,000 at 48.00
13.4%
19 Feb 2019
BOLNO PAUL President and CEO
Sold, plan not stated 2×
$281.46K 7,733 at 36.40
2.8%
19 Feb 2019
Vargeese Chandra Senior VP, Drug Discovery
Sold, plan not stated
$75.71K 2,055 at 36.84
7.5%
19 Feb 2019
Panzara Michael A. Franchise Lead, Neurology
Sold, plan not stated
$67.67K 1,837 at 36.84
4.7%
19 Feb 2019
Francis Chris See Remarks
Sold, plan not stated
$62.96K 1,709 at 36.84
7.7%
19 Feb 2019
Regnante Keith Chief Financial Officer
Sold, plan not stated
$47.82K 1,298 at 36.84
7.6%
Showing 1–50 of 78. Page 1 of 2 Older →